Osteopore invests in stem cell, aging research

Tissue regeneration developer Osteopore is to invest in a new entity, Regen SPV, to be setup by scientists Dr Xianmin Zeng and Dr Brian Kennedy.

Regen SPV aims to advance cutting-edge regenerative technologies, disease cures, and the promotion of geroscience and longevity.

Its work will continue to advance the broader understanding of aging and the application of regenerative medicine and cellular therapies to extend healthspan and combat age-related conditions.

Osteopore manufactures 3D-printed bioresorbable tissue implants and scaffolds, aiding the restoration of nerves, tissue and bone.

According to Osteopore: “These scaffolds are manufactured using a proprietary manufacturing technique that significantly reduces the post-surgery complications commonly associated with permanent implants.

“With Osteopore as a strategic investor, the Regen SPV will gain access to the company’s clinical and technical advisory panel, leveraging (the company's) extensive expertise in research and development, clinical trials, regulatory processes, and commercialisation to accelerate the Regen SPV’s innovation and growth.”

Dr Zeng is a leading expert in stem cell biology specialising in human embryonic stem cells and induced pluripotent stem cells (iPSC).

Dr Zeng is the founder of USA-based RxCell Inc, and her research focuses on neural development using iPSC to model neurodegenerative diseases.

Dr Kennedy's research focuses on the molecular mechanisms of aging and interventions that can extend health span, such as pharmaceuticals and lifestyle changes.

Dr Kennedy directs the Healthy Longevity Translational Research Programme at the National University of Singapore, where he is a distinguished Professor.

Picture: Osteopore/Honeycomb microstructure of Osteopore’s implant.